Kailera Therapeutics initiated with a Buy at Jefferies

Jefferies initiated coverage of Kailera Therapeutics (KLRA) with a Buy rating and $48 price target The firm says that in an “icreasingly competitive” obesity market, Kailera “shines with a complete incretin package.” The company’s franchise builds on a solid collaboration with Hengrui, who is taking Ribupatide to potential approval in China soon, the analyst tells investors in a research note.